Alpha–theta border EEG abnormalities in preclinical Huntington's disease

Ponomareva, Natalia; Klyushnikov, S. A.; Abramycheva, N.Y.; Malina, Daria; Scheglova, Nadejda; Фокин, В. Ф.; Ivanova-Smolenskaia, Irina; Иллариошкин, С. Н.

doi:10.1016/j.jns.2014.06.035

Cited by 26 publications

(30 citation statements)

References 61 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…The relative power of the 4–7 Hz range negatively correlated with DBS during REM sleep. Lazar et al and Ponomareva et al both examined smaller frequency bins, and they both found correlates in the alpha–theta border range (41, 43). …”

Section: Resultsmentioning

confidence: 99%

“…Ponomareva et al (43) approached the use of qEEG as a biomarker of HD in premanifest HDGECs and examined 1Hz frequency bins within the traditionally examined wave bands in premanifest and control subjects. It was also the first study to focus solely on pre-HD subjects using qEEG biomarkers (43).…”

Section: Resultsmentioning

confidence: 99%

“…It was also the first study to focus solely on pre-HD subjects using qEEG biomarkers (43). They found no significant differences between the relative power of pre-HD and control subjects when examining the broad frequency bands.…”

Section: Resultsmentioning

confidence: 99%

“…Absolute beta power was only observed to increase in one of the studies of HD subjects (49). Two of eight studies examined the relative power of 1 Hz frequency bins, particularly near the alpha–theta border (41, 43). One examined premanifest and early HD subjects relative to controls (43) and the other premanifest subjects relative to controls (41).…”

Section: Resultsmentioning

confidence: 99%

See 3 more Smart Citations

Quantitative Electroencephalographic Biomarkers in Preclinical and Human Studies of Huntington’s Disease: Are They Fit-for-Purpose for Treatment Development?

et al. 2017

View full text Add to dashboard Cite

A major focus in development of novel therapies for Huntington’s disease (HD) is identification of treatments that reduce the burden of mutant huntingtin (mHTT) protein in the brain. In order to identify and test the efficacy of such therapies, it is essential to have biomarkers that are sensitive to the effects of mHTT on brain function to determine whether the intervention has been effective at preventing toxicity in target brain systems before onset of clinical symptoms. Ideally, such biomarkers should have a plausible physiologic basis for detecting the effects of mHTT, be measureable both in preclinical models and human studies, be practical to measure serially in clinical trials, and be reliably measurable in HD gene expansion carriers (HDGECs), among other features. Quantitative electroencephalography (qEEG) fulfills many of these basic criteria of a “fit-for-purpose” biomarker. qEEG measures brain oscillatory activity that is regulated by the brain structures that are affected by mHTT in premanifest and early symptom individuals. The technology is practical to implement in the laboratory and is well tolerated by humans in clinical trials. The biomarkers are measureable across animal models and humans, with findings that appear to be detectable in HDGECs and translate across species. We review here the literature on recent developments in both preclinical and human studies of the use of qEEG biomarkers in HD, and the evidence for their usefulness as biomarkers to help guide development of novel mHTT lowering treatments.

show abstract

Section: Resultsmentioning

confidence: 99%

Section: Resultsmentioning

confidence: 99%

Section: Resultsmentioning

confidence: 99%

Section: Resultsmentioning

confidence: 99%

See 2 more Smart Citations

Quantitative Electroencephalographic Biomarkers in Preclinical and Human Studies of Huntington’s Disease: Are They Fit-for-Purpose for Treatment Development?

et al. 2017

View full text Add to dashboard Cite

show abstract

“…These results of fragmented sleep are in line with a recent paper showing major sleep disturbances in manifest HD patients that were also characterized by increased arousals and awakenings55 and data from transgenic animal models of HD showing that sleep quality as well as oscillatory brain activity (EEG) and circadian rhythmicity becomes gradually more disrupted as the disease progresses 11, 12, 14. Furthermore, it has recently been shown that resting EEG alterations in pre‐HD individuals may be related to the course of the pathological process and to HD endophenotype 43. These results are intriguing, because EEG activity reflects characteristics of cortical and subcortical neural activity and has the potential to become a biomarker for HD onset and progression in the future 56.…”

Section: Discussionmentioning

confidence: 99%

Sleep deficits but no metabolic deficits in premanifest Huntington's disease

Lázár

Panin

Goodman

et al. 2015

Annals of Neurology

107

View full text Add to dashboard Cite

ObjectiveHuntington disease (HD) is a fatal autosomal dominant, neurodegenerative condition characterized by progressively worsening motor and nonmotor problems including cognitive and neuropsychiatric disturbances, along with sleep abnormalities and weight loss. However, it is not known whether sleep disturbances and metabolic abnormalities underlying the weight loss are present at a premanifest stage.MethodsWe performed a comprehensive sleep and metabolic study in 38 premanifest gene carrier individuals and 36 age‐ and sex‐matched controls. The study consisted of 2 weeks of actigraphy at home, 2 nights of polysomnography and multiple sleep latency tests in the laboratory, and body composition assessment using dual energy x‐ray absorptiometry scanning with energy expenditure measured over 10 days at home by doubly labeled water and for 36 hours in the laboratory by indirect calorimetry along with detailed cognitive and clinical assessments. We performed a principal component analyses across all measures within each studied domain.ResultsCompared to controls, premanifest gene carriers had more disrupted sleep, which was best characterized by a fragmented sleep profile. These abnormalities, as well as a theta power (4–7Hz) decrease in rapid eye movement sleep, were associated with disease burden score. Objectively measured sleep problems coincided with the development of cognitive, affective, and subtle motor deficits and were not associated with any metabolic alterations.InterpretationThe results show that among the earliest abnormalities in premanifest HD is sleep disturbances. This raises questions as to where the pathology in HD begins and also whether it could drive some of the early features and even possibly the pathology. Ann Neurol 2015;78:630–648

show abstract

EEG Analysis of Neurodegenerative Diseases

2021

EEG Signal Processing and Machine Learning

View full text Add to dashboard Cite

Alpha–theta border EEG abnormalities in preclinical Huntington's disease

Cited by 26 publications

References 61 publications

Quantitative Electroencephalographic Biomarkers in Preclinical and Human Studies of Huntington’s Disease: Are They Fit-for-Purpose for Treatment Development?

Quantitative Electroencephalographic Biomarkers in Preclinical and Human Studies of Huntington’s Disease: Are They Fit-for-Purpose for Treatment Development?

Sleep deficits but no metabolic deficits in premanifest Huntington's disease

EEG Analysis of Neurodegenerative Diseases

Contact Info

Product

Resources

About